2:14 PM
 | 
Jan 05, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

Eisai's Lenvima gets Priority Review for HCC in China

Eisai Co. Ltd. (Tokyo:4523) said China FDA granted Priority Review to an NDA for Lenvima lenvatinib mesylate (Kisplyx - EU, E7080) to treat hepatocellular carcinoma (HCC). The company submitted...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >